{"id":"dapagliflozin-farxiga","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Genital mycotic infections"},{"rate":"5–10","effect":"Urinary tract infections"},{"rate":"5–10","effect":"Polyuria"},{"rate":"5–10","effect":"Hypotension"},{"rate":"0.1–0.5","effect":"Diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, dapagliflozin allows glucose to be excreted in the urine, thereby lowering blood glucose levels independently of insulin secretion. This mechanism also promotes modest osmotic diuresis and has cardioprotective and renoprotective effects beyond glycemic control.","oneSentence":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:41.944Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT04930549","phase":"PHASE2","title":"Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2022-10-18","conditions":"Renal Insufficiency, Chronic","enrollment":32},{"nctId":"NCT07338331","phase":"NA","title":"Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Galala University","startDate":"2023-04-04","conditions":"Diabete Type 2, Non Alcoholic Fatty Liver","enrollment":80},{"nctId":"NCT07325435","phase":"PHASE4","title":"Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaryAnn Banerji","startDate":"2024-12-21","conditions":"Type 2 Diabetes (T2DM)","enrollment":60},{"nctId":"NCT07295223","phase":"PHASE3","title":"Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-12-30","conditions":"Acute Myocardial Infarction With ST Elevation","enrollment":44},{"nctId":"NCT07297589","phase":"PHASE3","title":"Epicardial Cardiac Fat-CT (EPIC-CT)","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-12-30","conditions":"STEMI - ST Elevation Myocardial Infarction, Epicardial Fat","enrollment":136},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT07245069","phase":"PHASE2","title":"Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-02-01","conditions":"Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD)","enrollment":100},{"nctId":"NCT06072326","phase":"PHASE2","title":"dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-01","conditions":"Type 1 Diabetes Mellitus With Diabetic Nephropathy","enrollment":36},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT07077525","phase":"PHASE4","title":"Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-01","conditions":"Type 2 Diabetes","enrollment":196},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT07033585","phase":"PHASE2, PHASE3","title":"Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-06-15","conditions":"Type 2 Diabetes","enrollment":600},{"nctId":"NCT06890143","phase":"PHASE3","title":"The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-22","conditions":"Pediatric Hereditary Kidney Diseases","enrollment":44},{"nctId":"NCT06615674","phase":"PHASE4","title":"Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Yoga Yudhistira","startDate":"2024-09-21","conditions":"Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","enrollment":40},{"nctId":"NCT06420167","phase":"PHASE2","title":"DapagliFLOzin in Renal AL Amyloidosis (FLORAL)","status":"RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2024-07-11","conditions":"Renal AL Amyloidosis","enrollment":20},{"nctId":"NCT06576375","phase":"PHASE3","title":"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2024-09-02","conditions":"Polycystic Ovary Syndrome","enrollment":70},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":"Dilated Cardiomyopathy","enrollment":150},{"nctId":"NCT04004793","phase":"PHASE4","title":"Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-06-12","conditions":"Type 2 Diabetes","enrollment":328},{"nctId":"NCT06434025","phase":"PHASE3","title":"IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-05-24","conditions":"Heart Failure, Systolic, Iron Deficiencies","enrollment":99},{"nctId":"NCT05392959","phase":"PHASE4","title":"Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2022-06-06","conditions":"Diabetes Mellitus, Type 2","enrollment":4},{"nctId":"NCT06374043","phase":"PHASE4","title":"Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-05-11","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus","enrollment":20},{"nctId":"NCT06233045","phase":"PHASE1","title":"Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-07-23","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT06127212","phase":"NA","title":"Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2023-03-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT05710367","phase":"PHASE2","title":"Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients","status":"UNKNOWN","sponsor":"Albina Nowak, MD","startDate":"2023-08","conditions":"Fabry Disease","enrollment":46},{"nctId":"NCT04882358","phase":"NA","title":"Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion","status":"UNKNOWN","sponsor":"Sequana Medical N.V.","startDate":"2021-05-27","conditions":"Heart Failure, Volume Overload","enrollment":24},{"nctId":"NCT04956263","phase":"PHASE2","title":"A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Youngene Therapeutics Inc., Ltd.","startDate":"2021-06-17","conditions":"Diabetes, Diabetes Mellitus, Type 1, Type1diabetes","enrollment":19},{"nctId":"NCT03766750","phase":"PHASE3","title":"Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.","status":"WITHDRAWN","sponsor":"EMS","startDate":"2021-12","conditions":"Type2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT04697485","phase":"PHASE4","title":"Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-01-08","conditions":"HF - Heart Failure, Diabetes Mellitus","enrollment":""},{"nctId":"NCT04856007","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-12","conditions":"Healthy Volunteer","enrollment":80},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT04881006","phase":"PHASE1","title":"Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2020-12-10","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT04880993","phase":"PHASE1","title":"Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2020-12-14","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT04473417","phase":"PHASE1","title":"Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-08-04","conditions":"Healthy","enrollment":60},{"nctId":"NCT04193566","phase":"PHASE4","title":"Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2020-02-01","conditions":"Nephropathy, Hypoxia, Mitochondrial Alteration","enrollment":30},{"nctId":"NCT04570865","phase":"PHASE4","title":"Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®","status":"UNKNOWN","sponsor":"Scripps Health","startDate":"2020-12-01","conditions":"Heart Failure, Systolic","enrollment":100},{"nctId":"NCT04304560","phase":"PHASE2","title":"Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"Damanhour University","startDate":"2020-03","conditions":"Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2, Cardiomyopathies","enrollment":60},{"nctId":"NCT03364985","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-12-03","conditions":"Healthy","enrollment":123},{"nctId":"NCT02304081","phase":"PHASE4","title":"Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function","status":"COMPLETED","sponsor":"Prof. Dr. Thomas Forst","startDate":"2015-01","conditions":"Type2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT03089333","phase":"PHASE4","title":"Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2016-07","conditions":"Hypertension, Diabetes Mellitus, Type 2, Blood Pressure","enrollment":16},{"nctId":"NCT03377335","phase":"PHASE4","title":"Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes","status":"UNKNOWN","sponsor":"University of Palermo","startDate":"2017-12-22","conditions":"Type 2 Diabetes Mellitus","enrollment":186},{"nctId":"NCT02722239","phase":"PHASE1","title":"An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-03-30","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT02585804","phase":"PHASE4","title":"Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-09","conditions":"Focal Segmental Glomerulosclerosis","enrollment":10},{"nctId":"NCT03138356","phase":"PHASE1","title":"Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":126},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT01095653","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1179},{"nctId":"NCT02313220","phase":"PHASE2","title":"Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2014-12","conditions":"Obesity","enrollment":50},{"nctId":"NCT01002807","phase":"PHASE1","title":"Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":15},{"nctId":"NCT00859898","phase":"PHASE3","title":"Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":1093},{"nctId":"NCT01535677","phase":"PHASE1","title":"To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT02060201","phase":"PHASE1","title":"Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-02","conditions":"Type 2 Diabetes Mellitus","enrollment":72},{"nctId":"NCT01662999","phase":"PHASE1","title":"Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Forxiga"],"phase":"phase_3","status":"active","brandName":"Dapagliflozin Farxiga®","genericName":"Dapagliflozin Farxiga®","companyName":"October 6 University","companyId":"october-6-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}